GO:0004137 deoxycytidine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004137 (deoxycytidine kinase activity) catalyzes the phosphorylation of deoxycytidine to deoxycytidine monophosphate using a nucleoside triphosphate as the phosphate donor.
• The enzyme is a rate-limiting step in the salvage pathway for deoxycytidine and is essential for activating several clinically important nucleoside analog drugs, including gemcitabine and cytarabine [2,3,5].
• Deoxycytidine kinase activity is elevated in many cancer cells and is a determinant of sensitivity or resistance to nucleoside analog chemotherapy [2,5,7].
• The activity is regulated by substrate availability, feedback inhibition by dCTP, and cellular redox status, and can be modulated by hydrogen peroxide and nucleoside analogs [6,7].
• Altered deoxycytidine kinase activity is observed in hematological malignancies such as acute myeloid leukemia and chronic lymphocytic leukemia, where it correlates with drug response [5,8].
• Studying this activity requires a combination of enzymatic assays, molecular imaging, and CRISPR-based genetic models to dissect its role in disease and drug metabolism [1,6].
Description
Deoxycytidine kinase (dCK) is a key enzyme in the salvage pathway of deoxyribonucleoside metabolism, responsible for the phosphorylation of deoxycytidine to its monophosphate form. The Gene Ontology term GO:0004137, deoxycytidine kinase activity, describes the catalytic function of this enzyme: the transfer of a phosphate group from a nucleoside triphosphate to deoxycytidine, yielding deoxycytidine monophosphate and a nucleoside diphosphate. This activity is not only fundamental to nucleotide homeostasis but also determines the pharmacological activation of several anticancer and antiviral nucleoside analogs [2,3]. Because dCK activity is often dysregulated in cancer, it has become a focal point for both basic research and drug development [5,7]. Understanding the molecular mechanism, regulation, and disease relevance of GO:0004137 is therefore critical for researchers in oncology, pharmacology, and molecular biology.
deoxycytidine kinase activity At A Glance
| GO ID | GO:0004137 |
|---|---|
| GO term | deoxycytidine kinase activity |
| Ontology | molecular_function |
| Synonym | 2'-deoxycytidine kinase activity; arabinofuranosylcytosine kinase activity; Ara-C kinase activity; deoxycytidine-cytidine kinase activity; deoxycytidine kinase (phosphorylating); NTP:deoxycytidine 5'-phosphotransferase activity |
| Major function | Phosphorylation of deoxycytidine to deoxycytidine monophosphate using NTP as phosphate donor |
| Reaction | NTP + deoxycytidine = NDP + CMP |
| Substrates | Deoxycytidine, cytarabine (Ara-C), gemcitabine, other deoxycytidine analogs |
| Cofactors | Divalent cations (e.g., Mg2+) are typically required for kinase activity |
| Localization | Predominantly cytoplasmic, with some nuclear localization |
What Is GO:0004137?
Deoxycytidine kinase activity (GO:0004137) is defined as the catalysis of the reaction: NTP + deoxycytidine = NDP + CMP. In other words, it is the enzymatic activity that transfers a phosphate group from a nucleoside triphosphate (NTP) to deoxycytidine, producing deoxycytidine monophosphate (CMP) and a nucleoside diphosphate (NDP). This activity is synonymous with 2'-deoxycytidine kinase, arabinofuranosylcytosine kinase, Ara-C kinase, and deoxycytidine-cytidine kinase, reflecting its ability to phosphorylate both the natural substrate and several synthetic analogs.
Why Is deoxycytidine kinase activity Important in Cell Biology?
Deoxycytidine kinase activity is a critical node in nucleotide metabolism and a major determinant of cellular sensitivity to nucleoside analog drugs. It is the rate-limiting enzyme for the activation of gemcitabine and cytarabine, two frontline chemotherapeutics used in solid tumors and leukemias [2,3,5]. Moreover, dCK activity is frequently elevated in cancer cells, making it a potential biomarker and therapeutic target [2,7]. Its role in drug resistance and its regulation by cellular stress pathways further underscore its importance in cancer biology and pharmacology [6,8].
• Essential for the salvage pathway of deoxycytidine, maintaining dNTP pools for DNA synthesis and repair.
• Required for the activation of nucleoside analog prodrugs such as gemcitabine and cytarabine [2,3].
• Elevated activity in many cancer cells correlates with increased sensitivity to nucleoside analogs [2,5].
• Loss of activity or downregulation is associated with resistance to cytarabine in acute myeloid leukemia.
• Regulated by oxidative stress and nucleoside analogs, linking metabolism to redox signaling.
• Feedback inhibited by dCTP, ensuring balanced nucleotide pools.
• Potential target for molecular imaging of tumor proliferation using deoxycytidine-enhanced CEST MRI.
• Altered activity patterns in B-cell chronic lymphocytic leukemia suggest a role in disease progression.
• Modulated by hydrogen peroxide, indicating sensitivity to cellular redox state.
• Key determinant of gemcitabine-mediated radiosensitization in cancer therapy.
What Happens During deoxycytidine kinase activity?
Substrate Binding and Phosphoryl Transfer
In simple terms: The enzyme grabs deoxycytidine and a phosphate donor, then moves the phosphate onto deoxycytidine.
Deoxycytidine kinase binds its substrate deoxycytidine and a nucleoside triphosphate (NTP) in a ternary complex. The enzyme catalyzes the transfer of the gamma-phosphate from NTP to the 5'-hydroxyl group of deoxycytidine, producing deoxycytidine monophosphate (dCMP) and a nucleoside diphosphate (NDP). This reaction is essential for the salvage of deoxycytidine and for the activation of several nucleoside analogs, including cytarabine and gemcitabine [2,3].
Activation of Nucleoside Analog Prodrugs
In simple terms: The enzyme also activates certain drugs by adding a phosphate, turning them into their active forms.
Beyond its natural substrate, deoxycytidine kinase phosphorylates prodrugs such as cytarabine (Ara-C) and gemcitabine (dFdC), converting them to their monophosphate forms. This is the first and rate-limiting step in their activation to cytotoxic triphosphates that inhibit DNA synthesis [2,3]. Therefore, cellular dCK activity directly determines the efficacy of these chemotherapeutics.
Feedback Regulation by dCTP
In simple terms: The end product of the pathway can shut down the enzyme to keep things balanced.
Deoxycytidine kinase activity is subject to feedback inhibition by dCTP, the end product of the deoxycytidine salvage pathway. This ensures that intracellular dCTP pools do not become excessive, which could lead to mutagenesis or imbalance in dNTP pools. This regulation is critical for maintaining genomic stability and proper DNA replication.
Redox Sensitivity and Modulation by Hydrogen Peroxide
In simple terms: The enzyme's activity can be altered by oxidative stress.
Recent studies have shown that deoxycytidine kinase activity is modulated by hydrogen peroxide and nucleoside analogs. Oxidative stress can affect the enzyme's activity, potentially linking cellular redox status to nucleotide metabolism and drug response. This redox sensitivity may have implications for cancer therapy, where reactive oxygen species are often elevated.
Key Genes Involved in GO:0004137 deoxycytidine kinase activity
The following genes and proteins are directly involved in deoxycytidine kinase activity or its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DCK | Encodes deoxycytidine kinase, the enzyme responsible for GO:0004137 | Mutations or expression changes affect nucleoside analog sensitivity |
| CMPK1 | Phosphorylates dCMP to dCDP, downstream of dCK | Participates in the salvage pathway and gemcitabine activation |
| NME1 | Nucleoside diphosphate kinase, generates NTPs for dCK reaction | Supports phosphate donor supply for dCK activity |
| RRM1 | Ribonucleotide reductase, balances dNTP pools | Indirectly regulates dCK activity through dCTP feedback |
| RRM2 | Ribonucleotide reductase subunit, influences dNTP pools | Modulates feedback inhibition of dCK |
| TYMS | Thymidylate synthase, affects dCTP pools | Cross-talk with dCK pathway |
| DCTD | dCMP deaminase, catabolizes dCMP | Balances dCMP levels produced by dCK |
| NT5C | 5'-nucleotidase, dephosphorylates nucleosides | Counteracts dCK activity |
| ENT1 | Equilibrative nucleoside transporter, imports deoxycytidine | Determines substrate availability for dCK |
| ENT2 | Nucleoside transporter, imports deoxycytidine and analogs | Affects dCK-mediated drug activation |
| CNT1 | Concentrative nucleoside transporter, imports pyrimidines | Influences dCK substrate supply |
| CNT3 | Concentrative nucleoside transporter, broad specificity | Contributes to deoxycytidine uptake |
| AKT1 | Kinase that may regulate dCK phosphorylation | Potential post-translational regulation of dCK |
| ATM | DNA damage response kinase, may affect dCK expression | Links DNA damage to nucleotide metabolism |
| TP53 | Tumor suppressor, regulates dCK expression | Mutant p53 may alter dCK activity in cancer |
| MYC | Oncogene, drives proliferation and nucleotide demand | May upregulate dCK in cancer |
| KRAS | Oncogene, affects nucleoside metabolism | Mutant KRAS may influence dCK activity |
How Is deoxycytidine kinase activity Regulated?
Deoxycytidine kinase activity is regulated at multiple levels. Feedback inhibition by dCTP provides immediate control, ensuring balanced dNTP pools. Substrate availability, governed by nucleoside transporters, also modulates activity. Additionally, oxidative stress and hydrogen peroxide can affect dCK activity, linking redox signaling to nucleotide metabolism. Nucleoside analogs themselves can modulate dCK activity, potentially through stabilization or altered expression. In cancer cells, oncogenic signaling pathways such as MYC and KRAS may upregulate dCK expression to meet increased nucleotide demand.
deoxycytidine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DCK | Acute myeloid leukemia, drug resistance | DCK knockout AML cell lines, patient-derived xenografts |
| DCK | Solid tumors, gemcitabine sensitivity | DCK overexpression and knockout in pancreatic cancer cells |
| DCK | B-cell chronic lymphocytic leukemia | Primary CLL cells with modulated DCK expression |
| DCK | Cancer imaging | Xenograft models for CEST MRI |
| DCK | Redox regulation | Cell lines treated with hydrogen peroxide |
Deoxycytidine Kinase Activity in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a hematological malignancy where deoxycytidine kinase activity is a critical determinant of response to cytarabine, a cornerstone of therapy. Studies have shown that patients with resistant AML often have lower dCK activity compared to sensitive patients, suggesting that dCK activity levels can predict clinical outcome. Therefore, measuring dCK activity may help stratify patients for cytarabine-based regimens.
Role in Solid Tumors and Gemcitabine Sensitivity
In solid tumors, deoxycytidine kinase activity is essential for the activation of gemcitabine, a nucleoside analog used in pancreatic, lung, and breast cancers. High dCK activity correlates with increased gemcitabine sensitivity, while low activity contributes to resistance [2,3]. Additionally, dCK activity is involved in gemcitabine-mediated radiosensitization, making it a target for combination therapies.
Chronic Lymphocytic Leukemia and dCK Activity Patterns
In B-cell chronic lymphocytic leukemia (CLL), the pattern of deoxycytidine kinase activity relative to deoxyguanosine kinase activity and mRNA expression has been studied in untreated patients. These patterns may reflect disease biology and influence responsiveness to nucleoside analogs. Understanding dCK activity in CLL could lead to personalized treatment approaches.
Deoxycytidine Kinase as an Imaging Biomarker
Deoxycytidine-enhanced CEST MRI has been developed to image deoxycytidine kinase activity in vivo. This non-invasive technique can visualize tumor proliferation and dCK activity, potentially guiding therapy with nucleoside analogs. Such imaging biomarkers could be valuable for assessing drug target engagement and early treatment response.
From deoxycytidine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DCK confer resistance to cytarabine? | DCK knockout cell lines (CRISPR/Cas9) |
| Does a specific point mutation in DCK alter substrate specificity? | Point-mutation knock-in cell lines |
| Can DCK activity be imaged non-invasively? | DCK-overexpressing xenografts with CEST MRI |
| How does DCK expression affect gemcitabine sensitivity? | DCK overexpression and knockdown models |
| What is the role of DCK in normal hematopoiesis? | Conditional DCK knockout mice |
| Does dCTP feedback regulation involve specific DCK residues? | Site-directed mutagenesis and knock-in models |
How to Study the deoxycytidine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric kinase assay | Phosphorylation of deoxycytidine to dCMP | Quantifying dCK activity in cell lysates |
| CEST MRI | Deoxycytidine kinase activity in vivo | Non-invasive imaging of tumor proliferation |
| qRT-PCR | DCK mRNA expression | Correlating expression with activity |
| Western blot | dCK protein levels | Assessing protein expression and stability |
| CRISPR knockout screening | Genes affecting nucleoside analog sensitivity | Identifying modifiers of dCK pathway |
| Enzyme-linked immunosorbent assay (ELISA) | dCK protein concentration | High-throughput quantification |
| Mass spectrometry | dNTP pools and dCK reaction products | Metabolic profiling |
Enzymatic Assays for Deoxycytidine Kinase Activity
Classical radiometric or spectrophotometric assays measure the conversion of deoxycytidine to dCMP using radiolabeled substrates or coupled enzyme reactions. These assays are used to quantify dCK activity in cell lysates and to assess the impact of inhibitors or mutations [2,5].
Molecular Imaging of dCK Activity
Deoxycytidine-enhanced CEST MRI allows non-invasive imaging of dCK activity in vivo. This technique exploits the chemical exchange saturation transfer effect of deoxycytidine and its phosphorylated product, providing a readout of enzyme activity in tumors.
Gene Expression Analysis
Quantitative RT-PCR and RNA-seq are used to measure DCK mRNA levels in cells and tissues. Correlating mRNA expression with enzyme activity provides insights into transcriptional and post-transcriptional regulation.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to nucleoside analogs, including DCK and its regulators. These screens help uncover pathways that interact with dCK activity and drug response.
How CRISPR Can Be Used to Study GO:0004137 deoxycytidine kinase activity
Knockout
CRISPR/Cas9-mediated knockout of DCK is used to create isogenic cell lines lacking deoxycytidine kinase activity. These models are essential for studying the role of dCK in drug sensitivity, nucleotide metabolism, and DNA repair. For example, DCK knockout cells show resistance to cytarabine and gemcitabine, confirming the enzyme's role in prodrug activation.
Point Mutation
Point mutations in DCK can be introduced using CRISPR base editing or homology-directed repair to study structure-function relationships. Mutations in the catalytic domain or substrate-binding pocket can alter enzyme kinetics, substrate specificity, or feedback inhibition, providing insights into the molecular mechanism of GO:0004137.
Knock-in
Knock-in of tagged DCK (e.g., FLAG or GFP) allows for affinity purification and live-cell imaging of the enzyme. This approach helps track dCK localization, interactions, and dynamics in response to drugs or stress. Knock-in of disease-associated mutations can also model altered dCK activity in leukemia.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of DCK is used to increase deoxycytidine kinase activity in cells. Overexpression models are valuable for studying the effects of elevated dCK on nucleoside analog sensitivity, dNTP pool balance, and tumorigenesis. They also enable imaging studies with deoxycytidine-enhanced CEST MRI.
How EDITGENE Supports deoxycytidine kinase activity Research
Researchers studying deoxycytidine kinase activity-related genes often need to determine whether a candidate gene is causally involved in drug response, nucleotide metabolism, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling rigorous functional studies of GO:0004137 and its regulatory network.
Contact EDITGENE today to design your custom CRISPR model for deoxycytidine kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DCK Knockout HEK293 Cell Line | EDJ-KQ4426 | Human | 1633 | Details Get a Quote |
| TK2 Knockout HEK293 Cell Line | EDJ-KQ17908 | Human | 7084 | Details Get a Quote |
| DCK Knockout A-549 Cell Line | EDJ-KQ26962 | Human | 1633 | Details Get a Quote |
| DCK Knockout HCT 116 Cell Line | EDJ-KQ26963 | Human | 1633 | Details Get a Quote |
| DCK Knockout HeLa Cell Line | EDJ-KQ26964 | Human | 1633 | Details Get a Quote |
| TK2 Knockout A-549 Cell Line | EDJ-KQ25698 | Human | 7084 | Details Get a Quote |
| TK2 Knockout HCT 116 Cell Line | EDJ-KQ25699 | Human | 7084 | Details Get a Quote |
| TK2 Knockout HeLa Cell Line | EDJ-KQ25700 | Human | 7084 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About deoxycytidine kinase activity
What is deoxycytidine kinase activity?
Deoxycytidine kinase activity (GO:0004137) is the enzymatic function that catalyzes the phosphorylation of deoxycytidine to deoxycytidine monophosphate using a nucleoside triphosphate as the phosphate donor.
What genes are involved in deoxycytidine kinase activity?
The primary gene is DCK, which encodes the enzyme. Other genes such as CMPK1, NME1, and nucleoside transporters (ENT1, ENT2) also influence the pathway.
How is deoxycytidine kinase activity measured?
It can be measured using radiometric kinase assays, molecular imaging (CEST MRI), or by monitoring downstream metabolites [1,2].
Why is deoxycytidine kinase activity important in cancer?
It activates nucleoside analog drugs like gemcitabine and cytarabine, and its activity levels correlate with drug sensitivity in leukemia and solid tumors [2,3,5].
What diseases are associated with altered deoxycytidine kinase activity?
Acute myeloid leukemia, chronic lymphocytic leukemia, and solid tumors often show altered dCK activity, affecting drug response [5,8].
Can deoxycytidine kinase activity be imaged in vivo?
Yes, deoxycytidine-enhanced CEST MRI has been used to non-invasively image dCK activity in tumors.
How is deoxycytidine kinase activity regulated?
It is regulated by feedback inhibition by dCTP, substrate availability, and redox status, including modulation by hydrogen peroxide [6,7].
What is the reaction catalyzed by deoxycytidine kinase?
NTP + deoxycytidine = NDP + CMP, where NTP is a nucleoside triphosphate.
What are the synonyms for deoxycytidine kinase activity?
Synonyms include 2'-deoxycytidine kinase activity, arabinofuranosylcytosine kinase activity, Ara-C kinase activity, and deoxycytidine-cytidine kinase activity.
How can CRISPR be used to study deoxycytidine kinase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of DCK to study its role in drug response and metabolism [5,7].
Conclusion
Deoxycytidine kinase activity (GO:0004137) is a fundamental enzymatic function in nucleotide salvage and drug metabolism, with critical implications for cancer therapy. Its role in activating nucleoside analogs and its dysregulation in leukemia and solid tumors make it a prime target for research and therapeutic intervention. By leveraging CRISPR-based models and advanced imaging techniques, researchers can further unravel the molecular mechanisms and regulatory networks of this important enzyme.
References
- 1. Han Z et al.. 2019. Molecular Imaging of Deoxycytidine Kinase Activity Using Deoxycytidine-Enhanced CEST MRI.. Cancer Res 79(10):2775-2783 PMID: 30940660
- 2. Singhal RL et al.. 1992. Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.. Oncol Res 4(11-12):517-22 PMID: 1299379
- 3. Grégoire V et al.. 2002. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.. Radiother Oncol 63(3):329-38 PMID: 12142097
- 4. Arnér ES et al.. 1995. Mammalian deoxyribonucleoside kinases.. Pharmacol Ther 67(2):155-86 PMID: 7494863
- 5. Veuger MJ et al.. 2002. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.. Eur J Haematol 69(3):171-8 PMID: 12406011
- 6. Sun R et al.. 2020. The expression and activity of thymidine kinase 1 and deoxycytidine kinase are modulated by hydrogen peroxide and nucleoside analogs.. Nucleosides Nucleotides Nucleic Acids 39(10-12):1347-1358 PMID: 32189555
- 7. Weber G et al.. 1993. Regulation of deoxycytidine kinase activity and inhibition by DFDC.. Adv Enzyme Regul 33:39-59 PMID: 8356916
- 8. Lotfi K et al.. 2006. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.. Biochem Pharmacol 71(6):882-90 PMID: 16436271
